Preventing and treating major opportunistic infections in AIDS

References

• Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence—United States, 1996. MMWR 1997; 46(8): 165–73
   PubMedGoogle Scholar
• Program and abstracts: 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: 1997 Jan 22–6; 65–224
   Google Scholar
• Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993; 329(26): 1922–6
   PubMed Web of Science ®Google Scholar
• Su TH, Martin WJ 2d. Pathogenesis and host response in Pneumocystis carinii pneumonia. Annu Rev Med 1994; 45: 261–72
   PubMedGoogle Scholar
• Telzak EE, Cote RJ, Gold JW, et al. Extrapulmonary Pneumocystis carimi infections. Rev Infect Dis 1990; 12(3): 380–6
   Google Scholar
• Lane HC, Laughon BE, Falloon J, et al. NIH conference: recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994; 120(11): 945–55 [Erratum, Ann Intern Med 1995; 122(4): 317]
   Google Scholar
• National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323(21): 1500–4
   PubMed Web of Science ®Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995; 21 Suppl 1: S32–43
   Google Scholar
• Dutch AIDS Treatment Group. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327(26): 1836–41
   Google Scholar
• Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995; 20(4): 849–53
   PubMedGoogle Scholar
• Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988; 108(4): 585–94
   PubMed Web of Science ®Google Scholar
• Wilcox CM, Schwartz DA, Clark WS. Esophageal ulceration in human immunodeficiency virus infection: causes, response to therapy, and long-term outcome. Ann Intern Med 1995; 123(2): 143–9
   Google Scholar
• Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326(4): 213–20 [Erratum, N Engl J Med 1992; 326(17): 1172]
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996; 114(1): 23–33
   Google Scholar
• Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994; 112(12): 1531–9
   PubMed Web of Science ®Google Scholar
• Roche Cooperative Oral Ganciclovir Study Group. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334(23): 1491–7
   Google Scholar
• Hardy WD. Lessons learned from HIV pathogenesis and therapy: implications for better management of cytomegalovirus disease. AIDS 1996; 10 Suppl 1: S31–5
   Google Scholar
• Havlik JA Jr, Horsburgh CR Jr, Metchock B, et al. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992; 165(3): 577–80
   Google Scholar
• Canadian HIV Trials Network Protocol 010 Study Group. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. ? Engl J Med 1996; 335(6): 377–83
   Google Scholar
• AIDS Clinical Trials Group Protocol 157 Study Team. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121(12): 905–11
   Google Scholar
• Chaisson RE, Keiser P, Pierce M, et al. Controlled trial of clarithromycin/ethambutol with or without clofazimine for Mycobacterium avium bacteremia in AIDS. Abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: 1996 Jan
   Google Scholar
• California Collaborative Treatment Group. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335(6): 392–8
   Google Scholar
• Centers for Disease Control and Prevention. Tuberculosis morbidity: United States, 1995. MMWR 1996; 45(18): 365–70
   Google Scholar
• American Thoracic Society and the Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149(5): 1359–74
   Google Scholar
• Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337(5): 315–20
   PubMed Web of Science ®Google Scholar
• Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994; 19(4): 684–6
   Google Scholar
• Stewart JA, Reef SE, Pellett PE, et al. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1: S114–20
   Google Scholar
• Krown SE. Acquired immunodeficiency syndrome-associated Kaposi's sarcoma: biology and management. Med Clin North Am 1997; 81(2): 471–94
   Google Scholar
• Smith PD. Infectious diarrheas in patients with AIDS. Gastroenterol Clin North Am 1993; 22(3): 535–48
   Google Scholar
• Mannheimer SB, Soave R. Protozoal infections in patients with AIDS: cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis. Infect Dis Clin North Am 1994; 8(2): 483–98
   Google Scholar
• Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327(5): 329–37
   PubMedGoogle Scholar
• Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995; 333(2): 83–8
   PubMedGoogle Scholar